VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PHIOPhio Pharmaceuticals Corp.
$1.03$12M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPHIOEarnings History

PHIO logoPhio Pharmaceuticals Corp. (PHIO) Earnings History

Net Loss

15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$11M
● Net Loss
TTM EPS (Diluted)
$-0.94
Per share, diluted
YoY EPS Growth
-59.3%
Declining
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-69.9%
Return on Assets-63.9%
Record Annual Net Income-$7MFY2024
Record Quarterly EPS$-0.20Q4 2025
Consecutive Profitable Years0years
Q1 2026
Net Income-$4M
EPS (Diluted)$-0.34
YoY Growth-59.3%Declining
QoQ Growth-68.8%Declining

Loading earnings history...

Phio Pharmaceuticals Corp. (PHIO) Earnings Overview

As of June 22, 2026, Phio Pharmaceuticals Corp. (PHIO) reported trailing twelve-month net income of -$11M, reflecting -59.3% year-over-year growth. The company earned $-0.94 per diluted share over the past four quarters.

Looking at the long-term picture, PHIO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2024.

Phio Pharmaceuticals Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including SRPT ($65M net income, -32.5% margin), ARWR (-$301M net income, -0.2% margin), ALNY ($577M net income, 8.4% margin), PHIO has comparable earnings metrics. Compare PHIO vs SRPT →

PHIO Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
PHIO logoPHIOCurrent
-$11M$-0.94--69.9%-59.3%—
SRPT logoSRPT
$65M$0.53-32.5%-53.5%-404.7%
ARWR logoARWR
-$301M$-2.11-0.2%-0.5%+99.8%
ALNY logoALNY
$577M$4.188.4%73.3%+206.9%
NTLA logoNTLA
-$395M$-3.33-609.9%-53.5%+27.4%
BEAM logoBEAM
-$65M$-0.63-57.2%-8.1%+82.3%
Best in group
Lowest in group

PHIO Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$9M-21.7%-$9M$-1.45--
2024-$7M+34.0%-$7M$-0.91--
2023-$11M+5.7%-$11M$-46.76--
2022-$11M+13.6%-$11M$-89.61--
2021-$13M-51.1%-$14M$-111.32--
2020-$9M+1.3%-$9M$-207.25--
2019-$9M-21.0%-$9M$-2074.18-42419.0%-42795.2%
2018-$7M+40.9%-$7M$-6218.35-5333.3%-5336.2%
2017-$12M-38.4%-$14M$-32801.22-83013.3%-93746.7%
2016-$9M+12.0%-$9M$-79282.81-47336.8%-47447.4%
2015-$10M-16.2%-$10M$-93029.39-30067.6%-30108.8%
2014-$9M+57.9%-$9M$-238075.91-12394.4%-12431.0%
2013-$21M-62.5%-$21M$-999999.00-5244.4%-5250.4%
2012-$13M-26.0%-$13M$-999999.00-13278.4%-13376.3%
2011-$10M--$13M$-999999.00--

Download Data

Export PHIO earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PHIO — Frequently Asked Questions

Quick answers to the most common questions about buying PHIO stock.

What is PHIO earnings per share (EPS)?

PHIO trailing twelve-month (TTM) diluted EPS is $-0.94, reflecting -59.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is Phio Pharmaceuticals Corp.'s net income?

Phio Pharmaceuticals Corp. (PHIO) trailing twelve-month net income is $-11M as of 2025. Earnings declined -59.3% year-over-year.

Is PHIO profitable?

PHIO is not currently profitable on a TTM basis, reporting a net loss of $-11M. Net margin is N/A. Investors should monitor for a return to profitability.

What is PHIO's earnings growth rate?

PHIO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are PHIO's profit margins?

Phio Pharmaceuticals Corp. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -69.9%.

Is PHIO growing earnings?

PHIO earnings are declining — EPS fell -59.3% year-over-year. TTM net income dropped to $-11M. This contrasts with the 5-year CAGR of N/A.

What was PHIO's best earnings year?

Phio Pharmaceuticals Corp.'s highest annual net income on record is $-7M, achieved in fiscal year 2024. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were PHIO's earnings last quarter?

PHIO's most recent reported quarter was Q1 2026. Net income was $-4M with diluted EPS of $-0.34. For a full breakdown of all quarters, see the quarterly earnings table on this page.

PHIO Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view